936129-66-7

Basic information

• Product Name: Benzyl 4-[(3-aminopropyl)amino]piperidine-1-carboxylate dihydrochloride
• Synonyms: Benzyl 4-[(3-aminopropyl)amino]piperidine-1-carboxylate dihydrochloride
• CAS NO: 936129-66-7
• Molecular Formula: C16H27Cl2N3O2
• Molecular Weight: 364.31048
• Mol File: 936129-66-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzyl 4-[(3-aminopropyl)amino]piperidine-1-carboxylate dihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl 4-[(3-aminopropyl)amino]piperidine-1-carboxylate dihydrochloride(936129-66-7)
• EPA Substance Registry System: Benzyl 4-[(3-aminopropyl)amino]piperidine-1-carboxylate dihydrochloride(936129-66-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 936129-66-7(Hazardous Substances Data)

Upstream product

• 936129-65-6 benzyl 4-({3-[(tert-butoxycarbonyl)amino]propyl}amino)piperidine-1-carboxylate 

Relevant articles and documents

BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS.

This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1 , R2, R3 and R4 are as defined herein.

Discovery of a tetrahydropyrimidin-2(1 H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor

Coagulation enzyme factor Xa (FXa) is a particularly promising target for the development of new anticoagulant agents. We previously reported the imidazo[1,5-c]imidazol-3-one derivative 1 as a potent and orally active FXa inhibitor. However, it was found that 1 predominantly undergoes hydrolysis upon incubation with human liver microsomes, and the human specific metabolic pathway made it difficult to predict the human pharmacokinetics. To address this issue, our synthetic efforts were focused on modification of the imidazo[1,5-c] imidazol-3-one moiety of the active metabolite 3a, derived from 1, which resulted in the discovery of the tetrahydropyrimidin-2(1H)-one derivative 5k as a highly potent and selective FXa inhibitor. Compound 5k showed no detectable amide bond cleavage in human liver microsomes, exhibited a good pharmacokinetic profile in monkeys, and had a potent antithrombotic efficacy in a rabbit model without prolongation of bleeding time. Compound 5k is currently under clinical development with the code name TAK-442.